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Introduction
Large cross-sectional studies using modern abdominal imaging 
modalities such as magnetic resonance imaging (MRI) or com-
puted tomography (CT) have shown that approximately 2% of the 
general population exhibit cystic lesions in the pancreas [1, 2]. 
Most of these lesions were found in asymptomatic patients who 
underwent abdominal imaging for non-pancreas-related abdomi-
nal symptoms including urologic, gynecologic, vascular, or other 
medical conditions [3]. The incidence of cystic pancreatic lesions 
increases with age and reaches a level of up to 10% in patients of 
70 years and older [1]. The majority of authors assume that a large 
proportion of these lesions represent small intraductal papillary 
mucinous neoplasms (IPMNs) of the pancreas [2, 4]. However, in 
the majority of cases there is no histopathological diagnosis avail-
able to confirm this assumption. IPMNs are a distinct entity of 
cystic pancreatic neoplasms characterized by mucin production, 
cystic dilation of the pancreatic ductal system, and intrapapillary 
epithelial growth [5, 6]. Moreover, IPMNs are believed to undergo 
an adenoma-carcinoma sequence eventually culminating in inva-
sive ductal adenocarcinoma over time [3]. Few issues in gastro-
intestinal medicine are discussed as controversially as the adequate 
management of patients with these pancreatic lesions [4]. Particu-
larly the role of side-branch IPMNs that exclusively involve the 
branch duct system of the pancreas is not entirely understood [7–
9]. While a number of clinical series have shown that conservative 
observation of small branch-duct IPMNs (BD-IPMNs) without 
specific risk factors is safe over extended time periods [10], other 
studies have reported that in a significant number of surgically re-
sected BD-IPMNs, high-grade dysplasia or even invasive carci-
noma was found on surgical pathology [11–14]. To date it is not 
known whether and which IPMNs harbor the risk of malignant 
transformation and over what time period malignant transforma-
tion develops. 
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Summary
Background: With the use of modern cross-sectional ab-
dominal imaging modalities, an increasing number of 
cystic pancreatic lesions are identified incidentally. Al-
though there is no pathological diagnosis available in 
most cases, it is believed that the majority of these le-
sions display small branch-duct intraductal papillary 
 mucinous neoplasms (BD-IPMNs) of the pancreas. Even 
though a number of large clinical series have been pub-
lished, many uncertainties remain with regard to this en-
tity of mucinous cystic neoplasms. Methods: Systematic 
literature review. Results: Main-duct (MD) and mixed-
type IPMNs harbor a high risk of malignant transforma-
tion. It is conceivable that most IPMNs with involvement 
of the main duct tend to progress to invasive carcinoma 
over time. Thus, formal oncologic resection is the treat-
ment of choice in surgically fit patients. In contrast, the 
data regarding BD-IPMN remain equivocal, resulting in 
conflicting concepts. To date, it is not clear whether and 
which BD-IPMNs progress to carcinoma and how long 
this progression takes. Conclusion: While patients with 
MD-IPMNs should undergo surgical resection if comor-
bidities and life expectancy permit this, the management 
of small BD-IPMNs remains controversial. Population-
based studies with long-term follow-up are needed to 
define which cohort of patients can be observed safely 
without immediate resection.
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The aim of the present article is to summarize current evi-
dence about the natural history of IPMNs. Moreover, the reader 
should gain insights into the current controversial discussion 
about the adequate therapeutic management of patients with 
these lesions.
Epidemiology
IPMNs usually occur between the sixth and seventh decade of 
life and are mostly located in the head of the pancreas [10, 15, 16]. 
Considering all IPMN patients, an almost equal gender distri-
bution is found; however, more recent studies suggest that BD- 
IPMNs may occur slightly more often in females [17, 18]. While 
older studies have reported that approximately 25% of IPMNs are 
asymptomatic at the time of discovery [19, 20], recent series found 
that up to 60% of cystic pancreatic neoplasms are discovered acci-
dentally [18, 21]. When patients with IPMN present with symp-
toms, they frequently suffer from abdominal pain, weight loss, 
jaundice, steatorrhea, new onset of diabetes, or pancreatitis [15, 20, 
22, 23]. Most IPMNs occur spontaneously and without evidence of 
a systemic or familiar disease. However, it has been reported that 
IPMNs may also arise in the background of inherited syndromes 
such as Peutz-Jeghers syndrome [24] or familial adenomatous 
polyposis [25]. A small subset of patients with IPMN is associated 
with a specific phenotype of familial pancreatic cancer [26]. Beside 
familial pancreatic cancer, patients with IPMN are in general at a 
higher risk of developing concomitant pancreatic cancer, either 
synchronously or metachronously. This is an important observa-
tion because it indicates that resection of an IPMN only reduces 
the risk of developing pancreatic cancer but does not abolish it. 
The risk has been described to be as high as 10% [27], and there is 
growing evidence that patients with IPMN, as opposed to patients 
suffering from spontaneous ductal adenocarcinoma, are also at a 
higher risk of developing primary extrapancreatic malignancy [28]. 
For example, patients with IPMNs have a significantly higher risk 
of harboring colon polyps with consecutive colon cancer compared 
to the general population. Therefore, colonoscopy should be con-
sidered in all IPMN patients for screening purposes [29]. 
Pathological and Histopathological Background
Macroscopically, IPMNs appear as mucin-producing, predomi-
nantly papillary cystic neoplasms that probably arise from the epi-
thelium of the main pancreatic duct (MD-IPMN), from its side 
branches (BD-IPMN), or from both (mixed-type IPMN) [30]. It 
remains controversial whether mixed-type IPMNs arise from ei-
ther MD- or BD-IPMNs or if they represent a distinct entity [8]. 
The majority of IPMNs occur in the head or uncinate process of 
the pancreas [16, 23]. However, in approximately 15% of cases the 
lesions are multifocal, eventually involving the entire pancreatic 
gland [7, 23]. In some cases, the lesion presents as multicentric, 
forming clusters of cysts [31].
Considering the histopathological examination, surgically re-
sected IPMNs frequently display a wide range of dysplasia ranging 
from low-grade and moderate epithelial dysplasia (formally called 
‘adenoma’ and ‘borderline’ lesions, respectively) way through to 
high-grade dysplasia (‘carcinoma in situ’) and frank invasive ade-
nocarcinoma. Since a time lag of approximately 5 years was ob-
served between patients presenting with benign IPMN and those 
presenting with malignant IPMN including high-grade dysplasia 
and adenocarcinoma [6], current thinking is that a progression 
from preexisting low-grade dysplastic lesions to frank invasive can-
cer develops over time [32]. It has been reported that this disease 
progression is associated with cumulative genetic alterations, in-
cluding a number of mutations known from sporadic ductal ade-
nocarcinoma such as KRAS and TP53 [33].
Beside the location of the IPMN with regard to involvement of 
the main pancreatic duct or its side branches, it has recently be-
come clear that four histological subtypes of IPMNs can be distin-
guished [34]: gastric, intestinal, pancreatobiliary, and oncocytic. 
These subtypes can be distinguished by morphology only as well as 
by their characteristic mucin expression pattern, particularly with 
regard to MUC1, MUC2, and MUC5AC. There is growing evi-
dence that these four subtypes are associated with a different risk of 
malignant transformation and different clinical outcomes. Con-
cerning invasive carcinoma arising in IPMN, three distinct histo-
logical subtypes can be distinguished: tubular, colloid, and onco-
cytic [30]. Analyzing the outcome of these three subtypes of IPMN, 
it has been observed that the more favorable outcome of patients 
with invasive IPMN compared to sporadic ductal adenocarcinoma 
[6, 20, 23, 35] can only be demonstrated for colloid and oncocytic 
carcinomas [36]. In contrast, tubular adenocarcinoma was associ-
ated with an even poorer outcome compared to that of sporadic 
pancreatic cancer [36].
Today, it is widely accepted that MD-IPMNs exhibit a signifi-
cantly higher risk of malignant transformation than BD-IPMNs 
[10]. The risk of harboring malignancy in MD-IPMNs is as high as 
45% for invasive carcinoma, with an additional risk of 20% for har-
boring high-grade dysplasia (carcinoma in situ) [37]. Therefore, 
international guidelines recommend surgical resection for MD- 
and mixed-type IPMNs provided that the patient is an adequate 
candidate for surgery [10, 38] and that comorbidity and life ex-
pectancy do not preclude this option. In contrast, it has been pro-
posed to conservatively observe small BD-IPMNs without immedi-
ate resection. In recent years, a number of clinical series have been 
reported demonstrating the natural course of BD-IPMNs. Due to 
conflicting results of these studies and the difficulty to correctly 
diagnose malignancy in BD-IPMNs preoperatively, there remain 
great differences in the management recommendations – particu-
larly for small and asymptomatic BD-IPMNs [39].
Diagnostic Work-Up for Cystic Pancreatic Lesions
The diagnostic work-up for cystic lesions of the pancreas should 
definitely include thin-slice cross-sectional studies by CT scan or 
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MRI [40]. Using these modalities, detailed information about the 
location, cyst size, and potential relationship to blood vessels or 
other structures can be obtained. A dilation of the main pancreatic 
duct of ˰1 cm strongly suggests MD-IPMN, whereas a mucinous 
cystic lesion with communication to the main duct but without 
main duct dilation indicates BD-IPMN [41]. In addition to cross-
sectional imaging, a number of diagnostic means have been de-
scribed to be useful for correctly diagnosing IPMN. Endoscopic 
ultrasound (EUS) is widely established and recommended in the 
preoperative work-up of IPMNs [10] and, together with MRI/
MRCP (magnetic resonance cholangiopancreatography), better at 
detecting a communication between a cystic lesion and a pancre-
atic duct than CT scans. While some authors report that contrast-
enhanced EUS might be the most reliable tool to detect mural nod-
ules within the cystic lesion and to accordingly distinguish benign 
from high-risk/malignant IPMN [12, 42], others stated that mural 
nodules were found only in a minority of patients even when ma-
lignancy was already established [14, 43]. Furthermore, even 
though EUS in combination with fine needle aspiration (FNA) is 
often used to establish malignant transformation, a negative find-
ing does not always rule out malignancy [14]. In any case, it is ob-
vious that the use of EUS and FNA is strongly dependent on the 
experience of the operator [44]. Likewise, the evaluation of cytol-
ogy following cyst fluid aspiration correlates with the experience of 
the involved pathologist. While cyst fluid carcinoembryonic anti-
gen (CEA) was shown to be helpful in differentiating between be-
nign pancreatic pseudocysts and potentially malignant mucinous 
neoplasms [45], this parameter is of limited value in detecting ma-
lignancy in a mucinous lesion [46]. Recently, there has been evi-
dence that the serum tumor markers carbohydrate antigen 19-9 
(CA 19-9) and CEA are useful tools in distinguishing between be-
nign and invasive IPMN [18, 47]. However, these markers are not 
suitable to identify obligate precancerous lesions such as IPMNs 
with high-grade dysplasia that should be considered for surgical re-
section before malignant transformation occurs [47]. Once they 
are significantly elevated, the underlying tumor has often pro-
gressed to a stage where it is no longer operable. 
In summary, all available preoperative diagnostic tools have 
their limitations, and to date, there is no method available to dis-
criminate between benign and malignant IPMN with a high degree 
of certainty [13, 48]. This issue needs to be taken into account for 
choosing the best therapeutic approach in each individual patient 
although current guidelines suggest that a diameter of >3 cm and 
the presence of mural nodules should tip the balance in favor of a 
surgical approach.
Observational Studies for BD-IPMNs
The revised 2012 international consensus guidelines defined so-
called ‘worrisome features’ and ‘high-risk stigmata’ in order to de-
termine treatment recommendations for BD-IPMNs [10]. Accord-
ing to these treatment recommendations, patients identified with 
cystic lesions with ‘high-risk stigmata’ such as obstructive jaundice, 
an enhanced solid component within the cyst, or an increasing cyst 
size over time should undergo resection without further diagnostic 
evaluation. In contrast, for cysts with ‘worrisome features’ such as a 
cyst diameter of 3 cm or more, a thickened or enhancing cyst wall, 
or non-enhancing mural nodules, further diagnostic evaluation 
using EUS and FNA cytology is recommended. According to the 
current international guidelines, for asymptomatic cysts without 
any of these criteria, observation without immediate resection is 
recommended [10].
There are several large retrospective series available that vali-
dated the safety of these recommendations, encompassing more 
than 250 patients [23, 31, 49]. In none of the patients in these series 
who met the criteria for conservative observation but still under-
went pancreatic resection, cancer was found in the surgical speci-
men. Moreover, two recent studies confirmed the management 
guidelines, stating that following the observation recommenda-
tions is safe, whereas caution is advised for larger cystic lesions 
[18]: Jang et al. [50] reported that the new consensus guidelines 
provided better sensitivity, performance of factors predicting 
 malignancy, and balanced accuracy in the diagnosis of BD-IPMN 
malignancy. However, in contrast to other studies, Jang et al. [50] 
found that size alone was of limited accuracy for predicting malig-
nancy. Kobayashi et al. [51] reported that even when small mural 
nodules of <1 cm in diameter were found, observation was consid-
ered safe due to a low risk of malignant transformation. It should 
be noted here that while the mural nodules are an indicator for the 
risk of malignant transformation, the cancer does not necessarily 
arise from these nodules but in other portions of the cystic lesion 
[51]. Two recent series examined the risk of malignancy in BD- 
IPMNs with minimal or limited involvement of the main pancre-
atic duct [52, 53]. The authors of both studies conclude that pri-
mary surveillance of mixed-type IPMNs might be reasonable in 
selected patients. However, in the study of Roch et al. [53], among 
70 patients with mixed-type IPMN, 9 (13%) showed a progression 
to invasive carcinoma at a mean of 3.5 years (range: 1–9 years).
With regard to long-term follow-up studies, it remains un-
known when the neoplastic transformation from benign IPMNs to 
malignant lesions begins [9, 41]. It was suggested that disease pro-
gression occurs in 10–40% of the patients over 5 years, and the cal-
culated risk of cancer development is approximately 20% over 10 
years [9, 41]. It is well established that patients with IPMN are not 
only at a higher risk of developing IPMN-associated adenocarci-
noma but also of concomitant sporadic pancreatic cancer, either 
synchronously or metachronously [27]. In these cases, the IPMN 
indicates only the tip of the iceberg of a pancreatic field defect [54], 
leading to neoplastic changes over time [7]. It also denotes that re-
secting the IPMN does not necessarily abolish the risk of pancre-
atic cancer and that patients have to remain in postoperative sur-
veillance programs. In spite of such a follow-up, the progression to 
invasive cancer can be missed, as has been reported in patients who 
developed non-resectable pancreatic cancer during close follow-up 
after IPMN resection [9]. Not only this issue but also the potential 
of non-compliance during follow-up always has to be balanced 
against the risk of surgical resection in each individual patient [55].
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Surgical Series of Resected BD-IPMNs
According to the current guidelines, younger patients (<65 years) 
with a cyst size of >2 cm may also be candidates for resection [10], 
owing the cumulative risk of malignancy over time [12, 56] and their 
life expectancy. In recent years, an increasing number of surgical se-
ries has been published reporting that also small and unsuspicious 
BD-IPMNs may harbor a significant risk of malignancy in up to 20% 
of the cases [11–13, 57]. Wong et al. [14] found that high-grade dys-
plasia and adenocarcinoma were found in BD-IPMNs measuring 
less than 3 cm on EUS. Salvia et al. [48] reported that even in an ex-
perienced pancreatic center inaccurate preoperative diagnosis for 
cystic pancreatic lesions approached 22%. Likewise, Barron et al. 
[58] found that the preoperative radiographic IPMN type did not 
correlate with the final pathology in 25% of the patients. The authors 
suggest considering serum CA 19-9 as a complementary tool within 
the context of preoperative evaluation of cystic lesions [48]. Indeed, 
in a recent systematic review by Goh et al. [59], the limitations of the 
Sendai consensus guidelines were confirmed. The positive predictive 
value of the guidelines for predicting a malignant BD-IPMN was 
low, and some malignant lesions might be missed when diagnosis is 
based on these guidelines [59]. In this study, among 690 surgically 
resected BD-IPMNs, a malignancy rate of 24% was found. The 
strength of this study is that for each patient the final histological 
diagnosis was available. However, the incidence of malignancy only 
refers to patients who underwent surgery. It is possible that the real 
incidence of malignancy in BD-IPMNs is much lower because expe-
rienced clinicians were more likely to select patients at an increased 
risk of malignancy for resection. Surgeons often decide on resection 
based on a number of clinical factors that were not implemented in 
the international consensus guidelines, such as serum tumor mark-
ers, age, and previous extrapancreatic malignancy (e.g. breast can-
cer), and other unknown criteria [43, 60]. This assumption is also 
supported by the study of Roch et al. [53] who reported that the cri-
teria mentioned in the international consensus guidelines carried an 
unequal weight and were not cumulative in the prediction of risk for 
malignancy or invasiveness in IPMN.
In many cases, instead of a formal oncologic resection, a pan-
creatic parenchyma-sparing operation such as an enucleation can 
be considered for BD-IPMNs, even when they present multifocally 
(fig. 1). Depending on fresh-frozen section histology, the surgeon 
can decide whether a formal resection is necessary for the adequate 
treatment (fig. 2). Pancreatic enucleations can be performed with 
low morbidity and no mortality in high volume centers [61] and 
therefore represent an alternative to formal oncologic resections. 
In view of the fact that a significant risk of developing pancreatic 
cancer remains even after successful oncological IPMN resection, a 
more limited approach to either confirm or refute the malignant 
nature of a cystic lesion appears reasonable.
Summary of Current Evidence
To date, there remain conflicting results particularly concerning 
predictors of malignancy in both MD- and BD-IPMNs. Therefore, 
the natural history of this disease is not entirely understood. It is 
conceivable that in analogy to the natural history of colon polyps, 
an adenoma-carcinoma sequence exists in IPMNs. We believe that 
lesions with high-grade dysplasia have to be considered as high-
risk lesions that transform into invasive cancer over time as well as 
at a significant rate. With regard to current scientific knowledge 
and the absence of truly population-based (rather than case series-
based) studies, it is impossible to determine the real incidence of 
malignancy in small cystic lesions that have not been resected. It is 
Fig. 1. Two small 
BD-IPMNs in the head 
and corpus of the pan-
creas. A CT imaging 
showing two hypodense 
cystic lesions in the 
pancreatic head and 
corpus (arrows) of a 
52-year-old female. In 
maximal diameter, the 
lesions measured 2.2 
and 1.4 cm, respec-
tively. B T2-weighted 
MRI exhibiting both 
 lesions (arrows) and an 
unremarkable and thin 
pancreatic main duct 
(arrow heads).
Fig. 2. Surgical pancre-
atic enucleation of two 
small BD-IPMNs. Enu-
cleation of two small BD-
IPMNs (arrow heads) in 
the pancreatic head and 
corpus of a 52-year-old 
female (see fig. 1). A 
Enucleation of the BD-
IPMN measuring 2.2 cm 
in the pancreatic head. B 
Enucleation of the lesion 
measuring 1.4 cm in the 
corpus of the pancreas. 
For the surgical approach 
of this lesion, the dorsal 
part of the pancreatic 
gland was mobilized by 
dissection of the splenic 
vein. Both cystic lesions 
revealed a visible branch 
duct with direct connec-
tion to the main pancre-
atic duct (arrows).The final histological examination revealed two BD-IPMNs 
with low-grade epithelial dysplasia.
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probable that a number of small BD-IPMNs that are under surveil-
lance already harbor small areas of invasive cancer that would only 
be detected by histological examination after surgical resection. 
This would be in analogy to prostate cancer which can be present 
for many years before becoming clinically apparent [39]. In con-
trast, it is also conceivable that some BD-IPMNs do never progress 
or undergo malignant transformation. To date, it remains difficult 
and sometimes impossible to predict malignancy correctly in 
IPMNs. Without any doubt, the international consensus guidelines 
are helpful to identify patients with a high-risk profile. However, 
the indication for surgical resection always has to be seen individu-
ally in each patient. Factors such as age, life expectancy, comorbid-
ity, family history, or the willingness of the patient to undergo sur-
veillance have to be considered for an adequate therapeutic man-
agement. The decision making for a colon polyp with its adenoma-
carcinoma sequence is easy. A snare polypectomy carries a 
mortality risk of less than 1: 10,000, and morbidity is also very low. 
For prostate and breast cancer the decision is more difficult, and 
the pendulum has swung from concerns about catching all high-
risk or malignant lesions early (and resecting them) to a much 
greater concern about overtreatment because the associated mor-
bidity is significant and may outweigh the benefit of early detection 
and resection. For potentially malignant lesions of the pancreas the 
risk assessment is infinitely more complex: Not only is an over-
looked pancreatic cancer invariably a death sentence but the risk of 
overtreatment also carries the risk of a postsurgical mortality of 
3–8% and a morbidity of 30%.
It is well known that the prognosis of patients with resected 
IPMN with low-grade, moderate, or high-grade dysplasia is excel-
lent with a 10-year disease-specific survival of >95% for both MD- 
and BD-IPMN [37]. Recurrent disease is mainly found in patients 
with BD-IPMNs or in those with MD-IPMN and a false-negative 
transection margin because of denuded epithelium. For patients 
with invasive IPMN, the 5-year overall survival is around 40% [62]. 
To date, it remains controversial whether this better survival com-
pared to sporadic ductal adenocarcinoma is related to an earlier 
stage of presentation or due to a different biological behavior of 
mucinous cystic neoplasms – or both [3].
Conclusion
MD- and mixed-type IPMNs principally have to be considered as 
precursors to invasive adenocarcinoma of the pancreas. The tumors 
likely undergo an adenoma-carcinoma sequence eventually culmi-
nating in malignant neoplastic transformation. In contrast, the role 
of BD-IPMNs is not entirely understood. It is not clear whether all 
BD-IPMNs harbor a risk and malignant potential of malignant 
transformation and what the timeline of growth and progression 
might be. Therefore, the indication for surgical resection versus ob-
servation has to be individualized depending on a number of clinical 
factors. Clinical decision making should always be based on the ex-
pert opinion of an interdisciplinary team of gastroenterologists, ra-
diologists, and surgeons in a pancreatic high-volume center.
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